Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.54 |
| ▸ | APLNR | P35414 | 2/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153421 | 0.94 | MEN1 (0.61) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15384907 | 0.91 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15377334 | 0.87 | MEN1 (0.57) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL30063035 | 0.86 | MEN1 (0.79) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29674723 | 0.86 | MEN1 (0.79) | MEN1USP2POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL19125055 | 0.85 | MEN1 (0.78) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29367408 | 0.85 | MEN1 (0.72) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15376849 | 0.84 | MEN1 (0.67) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL838533 | 0.84 | MEN1 (0.68) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15377173 | 0.84 | MEN1 (0.75) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3294810-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | Blinkbio Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.